1. Home
  2. COLL vs LGIH Comparison

COLL vs LGIH Comparison

Compare COLL & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$37.27

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo LGI Homes Inc.

LGIH

LGI Homes Inc.

HOLD

Current Price

$44.52

Market Cap

1.3B

ML Signal

HOLD

Company Overview

Basic Information
Metric
COLL
LGIH
Founded
2002
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
COLL
LGIH
Price
$37.27
$44.52
Analyst Decision
Strong Buy
Hold
Analyst Count
6
5
Target Price
$50.83
$75.90
AVG Volume (30 Days)
364.8K
339.8K
Earning Date
05-28-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.73
3.12
Revenue
$780,567,000.00
$1,705,504,000.00
Revenue This Year
$6.07
$6.01
Revenue Next Year
N/A
$14.33
P/E Ratio
$21.50
$15.06
Revenue Growth
23.62
N/A
52 Week Low
$23.23
$39.70
52 Week High
$50.79
$77.38

Technical Indicators

Market Signals
Indicator
COLL
LGIH
Relative Strength Index (RSI) 21.42 30.01
Support Level $34.30 $41.82
Resistance Level $39.85 $55.90
Average True Range (ATR) 1.61 2.57
MACD -0.83 -1.29
Stochastic Oscillator 9.89 1.04

Price Performance

Historical Comparison
COLL
LGIH

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About LGIH LGI Homes Inc.

LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.

Share on Social Networks: